Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759862 | 1.00 | PDGFRA (0.57) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL30809578 | 0.94 | PDGFRA (0.49) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL29759446 | 0.94 | PDGFRA (0.49) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL24578084 | 0.94 | PDGFRA (0.49) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL29759938 | 0.92 | PDGFRA (0.59) | PDGFRACHRM1HRH3IRAK4POLQ | |
| SCHEMBL24577506 | 0.92 | PDGFRA (0.59) | PDGFRACHRM1HRH3IRAK4POLQ | |
| SCHEMBL24577838 | 0.90 | PDGFRA (0.58) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL29759575 | 0.90 | PDGFRA (0.58) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL24578944 | 0.89 | PDGFRA (0.43) | PDGFRACHRM1HRH3IRAK4CCNT1 | |
| SCHEMBL29759978 | 0.89 | PDGFRA (0.43) | PDGFRACHRM1HRH3IRAK4CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |